SCHEMBL4842934

SCHEMBL4842934

Clc1cnc2[nH]c(-c3ccc(NCCN4CCOCC4)cc3)nc2c1Nc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
PLK1 P53350 1/20 0.45
IKBKE Q14164 1/20 0.45
TBK1 Q9UHD2 1/20 0.45
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 2/20 0.43
HTT P42858 2/20 0.43
TSHR P16473 4/20 0.42
MAPK1 P28482 2/20 0.42
MAPT P10636 2/20 0.42
TERT O14746 1/20 0.42
LMNA P02545 3/20 0.42
CYP1A2 P05177 4/20 0.41
CYP3A4 P08684 4/20 0.41
CYP2D6 P10635 4/20 0.41
CYP2C19 P33261 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
HIF1A Q16665 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4842844 0.87 IKBKE (0.45) MEN1KMT2AIKBKETBK1RAB9A
SCHEMBL6246355 0.81 TBK1 (0.47) MEN1KMT2AIKBKETBK1ALDH1A1
SCHEMBL4838835 0.81 TBK1 (0.64) IKBKETBK1RAB9AALDH1A1KDM4E
SCHEMBL4838927 0.78 TBK1 (0.58) IKBKETBK1RAB9AALDH1A1KDM4E
SCHEMBL4838953 0.78 TBK1 (0.57) KMT2AIKBKETBK1RAB9AALDH1A1
SCHEMBL5255272 0.78 TBK1 (0.55) IKBKETBK1ALDH1A1KDM4EEGFR
SCHEMBL4150322 0.76 KDM4E (0.47) MEN1KMT2APLK1RAB9AALDH1A1
SCHEMBL4837291 0.76 BCL6 (0.46) MEN1KMT2AIKBKETBK1RAB9A
SCHEMBL4835004 0.74 TBK1 (0.60) IKBKETBK1RAB9AALDH1A1KDM4E
SCHEMBL4833993 0.73 TBK1 (0.79) IKBKETBK1RAB9AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US claimed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 MEN1 2592/4885KMT2A 2697/4885PLK1 1121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.